Press release
Alnylam Announces 2022 Product and Pipeline Goals and Provides Program Updates at R&D Day
− Introduces New Near-Term Opportunity for Vutrisiran in Stargardt Disease, Expected to Enter Phase 3 Development in Late 2022 – – Adds New Preclinical
About this update from Alnylam Pharmaceuticals, Inc.
[{"type":"text","content":"\n− Introduces New Near-Term Opportunity for Vutrisiran in Stargardt Disease, Expected to Enter Phase 3 Development in Late 2022 –\n\n– Adds New Preclinical Cardiovascular Disease Programs, GEMINI-CVR and “Gene X,” with Highly Transformative Potential –\n\n– Highlights Strong Progress in Extrahepatic Delivery of RNAi Therapeutics, Including Delivery in Muscle, Heart, and Adipose Tissue, and New CNS and Ocular Programs Including ALN-SOD in SOD-1-Specific Amyotrophic Lateral Sclerosis (ALS) –\n\n– Alnylam to Webcast its R&D Day Event Today at 8:30 a.m. ET –\n\n CAMBRIDGE, Mass.--(BUSINESS WIRE)--\nAlnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, is hosting a virtual R&D Day today. During the event, the Company plans to showcase its R&D progress, including its product and pipeline goals for 2022, focused on continued commercial execution of four RNAi therapeutic products, the potential launch of its fifth product, as well as advancement of early-, mid- and late-stage investigational programs.\n\n“At Alnylam, we are excited about the opportunity for RNAi therapeutics in rare and common diseases utilizing liver and extrahepatic delivery to realize the greatest potential for this new class of medicines in human health,” said Akshay Vaishnaw, M.D., Ph.D., President of R&D at Alnylam. “Our annual R&D Day will feature updates across our pipeline, including deep dive discussions on RNAi therapeutic opportunities in ATTR amyloidosis and hypertension. In addition, we’ll highlight an exciting new program opportunity for vutrisiran in an inherited retinopathy, Stargardt Disease, and will describe additional new programs that have the potential to provide a foundation for sustainable innovation. Finally, we’ll highlight the strong progress we have made in extrahepatic delivery of RNAi therapeutics that we believe could have broad applicability across human disease. These new advances are all a part of building Alnylam for the future and will play a critical role in helping us achieve our ‘Alnylam P5x25’ goals.”\n\n2022 Product and Pipeline Goals\n\nAlnylam intends to provide guidance on 2022 combined net product revenue for ONPATTRO®, GIVLAARI®, and OXLUMO® in association with its fourth quarter and full year 2021 financial results.\n\nPatisiran, a commercial-stage RNAi therapeutic targeting transthyretin (T...